{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T20:10:01Z","timestamp":1789071001348,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002998","name":"College ter Beoordeling van Geneesmiddelen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002998","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Prescribing recommendations, communication programmes, and mandatory electronic prescribing were implemented in Lithuania to promote responsible use of benzodiazepines and benzodiazepine-related drugs (BZRDs). We assessed the impact of policy measures on benzodiazepine\/BZRD prescribing patterns in Lithuania.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analysed utilisation of oral benzodiazepines\/BZRDs in Lithuania from 2018 to 2024, using national prescription data and wholesale medicines data. Benzodiazepines\/BZRDs included (1) anxiolytic benzodiazepines; (2) hypnotic benzodiazepines; and (3) BZRDs. The policy intervention period spanned from November 1, 2020, to July 1, 2021. We used ARIMA models to assess monthly incidence, prevalence, and long-term use prevalence (\u2265\u2009180 days) per 1,000 inhabitants. Besides, the numbers of defined daily doses (DDDs) prescribed and sold to pharmacies per 1,000 inhabitants were studied. We estimated baseline slopes, step changes after implementation, and changes in slopes after implementation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 717,590 patients received 6,974,059 prescriptions for benzodiazepines or BZRDs. Prior to implementing the policy measures, there were upward trends in incidence, prevalence, and long-term use prevalence across all classes. Following the implementation, monthly incidence stabilised and prevalence decelerated for anxiolytic benzodiazepines and BZRDs. The prevalence of hypnotic benzodiazepines showed a significant immediate reduction after implementation. Long-term use prevalence continued to increase for all benzodiazepine\/BZRD classes after implementation of the policy.<\/jats:p>\n                    <jats:p>Before the policy measures were implemented, monthly DDDs sold to pharmacies were gradually declining for anxiolytic benzodiazepines, but were\u00a0stable for other classes. In contrast, monthly DDDs prescribed were increasing across all classes. Following the policy measures, immediate reductions\u00a0in DDDs sold to pharmacies were observed, without changes in slopes. The prescribed and sold DDDs converged after implementing the policy\u00a0measures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>From a public health perspective, the policy measures implemented in 2020 and 2021 had only a limited impact on the prescribing patterns of\u00a0benzodiazepines and BZRDs in Lithuania. They continued to be used long-term, highlighting the persistence of potentially irrational prescribing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00228-025-03992-7","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T07:10:40Z","timestamp":1770361840000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of policy measures targeting benzodiazepines and Benzodiazepine-related drugs in Lithuania: interrupted time series analysis"],"prefix":"10.1007","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8892-9820","authenticated-orcid":false,"given":"Tomas","family":"Lasys","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2079-4816","authenticated-orcid":false,"given":"Sharon C.M.","family":"Essink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3086-446X","authenticated-orcid":false,"given":"Yared","family":"Santa-Ana-Tellez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3095-9530","authenticated-orcid":false,"given":"Satu J.","family":"Siiskonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7044-2443","authenticated-orcid":false,"given":"Daniala L.","family":"Weir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7506-1544","authenticated-orcid":false,"given":"Inge M.","family":"Zomerdijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9238-6999","authenticated-orcid":false,"given":"Rolf H.H.","family":"Groenwold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9197-7068","authenticated-orcid":false,"given":"Marie L.","family":"De Bruin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5623-9684","authenticated-orcid":false,"given":"Helga","family":"Gardarsdottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"3992_CR1","unstructured":"Bounds CG, Patel P (2024) Benzodiazepines. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK470159\/ Accessed 14 November 2024"},{"key":"3992_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2019.02.033","author":"VR Votaw","year":"2019","unstructured":"Votaw VR, Geyer R, Rieselbach MM, McHugh RK (2019) The epidemiology of benzodiazepine misuse: a systematic review. Drug Alcohol Depend. https:\/\/doi.org\/10.1016\/j.drugalcdep.2019.02.033","journal-title":"Drug Alcohol Depend"},{"key":"3992_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2015.09.003","author":"TAT Kurko","year":"2015","unstructured":"Kurko TAT et al (2015) Long-term use of benzodiazepines: definitions, prevalence and usage patterns \u2013 a systematic review of register-based studies. Eur Psychiatr. https:\/\/doi.org\/10.1016\/j.eurpsy.2015.09.003","journal-title":"Eur Psychiatr"},{"key":"3992_CR4","doi-asserted-by":"publisher","DOI":"10.9740\/mhc.2016.05.120","author":"A Schmitz","year":"2016","unstructured":"Schmitz A (2016) Benzodiazepine use, misuse, and abuse: a review. Ment Health Clin. https:\/\/doi.org\/10.9740\/mhc.2016.05.120","journal-title":"Ment Health Clin"},{"key":"3992_CR5","unstructured":"Etneris E, Gerasimavi\u010di\u016bt\u0117 V, Benzodiazepinai (2018) Lietuvos analiz\u0117. \u201eKurk Lietuvai; https:\/\/data.kurklt.lt\/wp-content\/uploads\/2023\/04\/1.-BZD_Lietuvos-analize_PDF.pdf Accessed 22 November 2024"},{"key":"3992_CR6","doi-asserted-by":"publisher","DOI":"10.1080\/08039488.2019.1707283","author":"J Harro","year":"2020","unstructured":"Harro J et al (2020) Comparison of psychotropic medication use in the Baltic countries. Nord J Psychiatry. https:\/\/doi.org\/10.1080\/08039488.2019.1707283","journal-title":"Nord J Psychiatry"},{"key":"3992_CR7","doi-asserted-by":"publisher","DOI":"10.53453\/ms.2023.2.14","author":"G Valauskait\u0117","year":"2023","unstructured":"Valauskait\u0117 G, Rep\u0161yt\u0117 G, Andriu\u0161kevi\u010di\u016bt\u0117 D, Eitmontait\u0117 D, Badaras R (2023) Fighting benzodiazepine misuse in lithuania: detoxification treatment results in the single-centre toxicology department. J Med Sci. https:\/\/doi.org\/10.53453\/ms.2023.2.14","journal-title":"J Med Sci"},{"key":"3992_CR8","doi-asserted-by":"publisher","DOI":"10.5200\/sm-hs.2018.027","author":"R Aranauskas","year":"2018","unstructured":"Aranauskas R, Vai\u010diulien\u0117 L (2018) \u0160eimos Gydytojo pacient\u0173, vartojan\u010di\u0173 benzodiazepinus, priklausomyb\u0117s i\u0161sivystymo tendencijos. Public Health. https:\/\/doi.org\/10.5200\/sm-hs.2018.027","journal-title":"Public Health"},{"key":"3992_CR9","unstructured":"Ministry of Health of the Republic of Lithuania. Kei\u010diamos s\u0105lygos popierini\u0173 recept\u0173 i\u0161ra\u0161ymui migdomiesiems ir raminamiesiems vaistam. sam.lrv.lt (2021) https:\/\/sam.lrv.lt\/lt\/news\/keiciamos-salygos-popieriniu-receptu-israsymui-migdomiesiems-ir-raminamiesiems-vaistams\/ Accessed 17 April 2025"},{"key":"3992_CR10","unstructured":"Order of the Minister of Health of the Republic of Lithuania Order No. V-1610 (2020) D\u0117l Benzodiazepin\u0173 ir benzodiazepin\u0173 dariniams priskiriam\u0173 bei pana\u0161aus veikimo mechanizmo vaistini\u0173 preparat\u0173 skyrimo ir vartojimo ma\u017einimo ar nutraukimo metodini\u0173 rekomendacij\u0173 patvirtinimo. Ministry of Health of the Republic of Lithuania; https:\/\/e-seimas.lrs.lt\/portal\/legalAct\/lt\/TAD\/18ccfed0c01711eaae0db016672cba9c> Accessed 17 April 2025"},{"key":"3992_CR11","unstructured":"Lietuvos Respublikos sveikatos apsaugos ministro \u012esakymas V-112. D\u0117l Recept\u0173 ra\u0161ymo ir vaistini\u0173 preparat\u0173, medicinos priemoni\u0173 (medicinos prietais\u0173) ir kompensuojam\u0173j\u0173 medicinos pagalbos priemoni\u0173 i\u0161davimo (pardavimo) vaistin\u0117se gyventojams ir popierini\u0173 recept\u0173 saugojimo, i\u0161davus (pardavus) vaistinius preparatus, medicinos priemones (medicinos prietaisus) ir kompensuojam\u0105sias medicinos pagalbos priemones vaistin\u0117je, taisykli\u0173 patvirtinimo (2002) https:\/\/e-seimas.lrs.lt\/portal\/legalAct\/lt\/TAD\/TAIS.162242\/asr Accessed 17 April 2025"},{"key":"3992_CR12","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyaf118","author":"J Juodakis","year":"2025","unstructured":"Juodakis J et al (2025) Data resource profile: the Lithuanian health data reuse pathway. Int J Epidemiol. https:\/\/doi.org\/10.1093\/ije\/dyaf118","journal-title":"Int J Epidemiol"},{"key":"3992_CR13","unstructured":"Government of the Republic of Lithuania. Decree No. 1057. D\u0117l elektronin\u0117s sveikatos paslaug\u0173 ir bendradarbiavimo infrastrukt\u016bros informacin\u0117s sistemos nuostat\u0173 patvirtinimo. Government of the Republic of Lithuania (2011) https:\/\/e-seimas.lrs.lt\/portal\/legalAct\/lt\/TAD\/TAIS.406145?jfwid=11dyhel9hb Accessed 17 April 2025"},{"key":"3992_CR14","unstructured":"Order of the Minister of Health of the Republic of Lithuania Order No. V-657 (2015) D\u0117l Elektronin\u0117s sveikatos paslaug\u0173 ir bendradarbiavimo infrastrukt\u016bros informacin\u0117s sistemos naudojimo tvarkos apra\u0161o patvirtinimo. Ministry of Health of the Republic of Lithuania; https:\/\/e-seimas.lrs.lt\/portal\/legalAct\/lt\/TAD\/49e35880064e11e5b0d3e1beb7dd5516\/DBphunVBNn> Accessed 20 May 2025"},{"key":"3992_CR15","unstructured":"Lithuanian State Medicines Control Agency. Vaist\u0173 suvartojimo ataskaita. State Medicines Control Agency (2024) https:\/\/vvkt.lrv.lt\/lt\/svarbi-informacija\/vaistu-suvartojimo-2023-m-ataskaita_svarbi_informacija\/ Accessed 20 May 2025"},{"key":"3992_CR16","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology (2024) Guidelines for ATC classification and DDD assignment 2024. whocc.no. 2023\u2009https:\/\/atcddd.fhi.no\/atc_ddd_index\/ Accessed 16 September"},{"issue":"7","key":"3992_CR17","first-page":"2121","volume":"61","author":"LP Longo","year":"2000","unstructured":"Longo LP, Johnson B (2000) Addiction: Part I. Benzodiazepines\u2014side effects, abuse risk and alternatives. Am Fam Physician 61(7):2121\u20132128","journal-title":"Am Fam Physician"},{"key":"3992_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2012.04418.x","author":"M Lader","year":"2014","unstructured":"Lader M (2014) Benzodiazepine harm: how can it be reduced? Br J Clin Pharmacol. https:\/\/doi.org\/10.1111\/j.1365-2125.2012.04418.x","journal-title":"Br J Clin Pharmacol"},{"key":"3992_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-021-01235-8","author":"AL Schaffer","year":"2021","unstructured":"Schaffer AL, Dobbins TA, Pearson S-A (2021) Interrupted time series analysis using autoregressive integrated moving average (ARIMA) models: a guide for evaluating large-scale health interventions. BMC Med Res Methodol. https:\/\/doi.org\/10.1186\/s12874-021-01235-8","journal-title":"BMC Med Res Methodol"},{"key":"3992_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0228495","author":"P Caillet","year":"2020","unstructured":"Caillet P, Rousselet M, Gerardin M, Jolliet P, Victorri-Vigneau C (2020) Prevalence of zolpidem use in France halved after secure prescription pads implementation in 2017: A SNDS database nested cohort study. PLoS One. https:\/\/doi.org\/10.1371\/journal.pone.0228495","journal-title":"PLoS One"},{"key":"3992_CR21","doi-asserted-by":"publisher","DOI":"10.1370\/afm.2556","author":"N Rousselot","year":"2020","unstructured":"Rousselot N, Pariente A, Mansiaux Y, Victorri-Vigneau C (2020) Impact of secured prescription implementation for zolpidem on hypnotics use in France: A time-series analysis on National data. Ann Fam Med. https:\/\/doi.org\/10.1370\/afm.2556","journal-title":"Ann Fam Med"},{"key":"3992_CR22","doi-asserted-by":"publisher","DOI":"10.9778\/cmajo.20180121","author":"DL Weir","year":"2018","unstructured":"Weir DL, Samanani S, Gilani F, Jess E, Eurich DT (2018) Benzodiazepine receptor agonist dispensations in Alberta: a population-based descriptive study. cmajo. https:\/\/doi.org\/10.9778\/cmajo.20180121","journal-title":"cmajo"},{"key":"3992_CR23","first-page":"224","volume":"88","author":"B Johnson","year":"2013","unstructured":"Johnson B, Streltzer J (2013) Risks associated with long-term benzodiazepine use. Am Fam Physician 88:224\u2013226","journal-title":"Am Fam Physician"},{"key":"3992_CR24","doi-asserted-by":"publisher","DOI":"10.1177\/00912174231166252","author":"DL Louie","year":"2023","unstructured":"Louie DL, Jegede OO, Hermes GL (2023) Chronic use of benzodiazepines: the problem that persists. Int J Psychiatry Med. https:\/\/doi.org\/10.1177\/00912174231166252","journal-title":"Int J Psychiatry Med"},{"key":"3992_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s00127-011-0344-1","author":"CM Sonnenberg","year":"2012","unstructured":"Sonnenberg CM, Bierman EJM, Deeg DJH, Comijs HC, van Tilburg W, Beekman ATF (2012) Ten-year trends in benzodiazepine use in the Dutch population. Soc Psychiatry Psychiatr Epidemiol. https:\/\/doi.org\/10.1007\/s00127-011-0344-1","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"key":"3992_CR26","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.15292","author":"J Brett","year":"2018","unstructured":"Brett J et al (2018) Benzodiazepine use in older adults in the United States, Ontario, and Australia from 2010 to 2016. J Am Geriatr Soc. https:\/\/doi.org\/10.1111\/jgs.15292","journal-title":"J Am Geriatr Soc"},{"key":"3992_CR27","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2014.1763","author":"M Olfson","year":"2015","unstructured":"Olfson M, King M, Schoenbaum M (2015) Benzodiazepine use in the united States. JAMA Psychiatry. https:\/\/doi.org\/10.1001\/jamapsychiatry.2014.1763","journal-title":"JAMA Psychiatry"},{"key":"3992_CR28","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.19029","author":"H Taipale","year":"2020","unstructured":"Taipale H et al (2020) Incidence of and characteristics associated with long-term benzodiazepine use in Finland. JAMA Netw Open. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.19029","journal-title":"JAMA Netw Open"},{"key":"3992_CR29","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.7399","author":"SD Agarwal","year":"2019","unstructured":"Agarwal SD, Landon BE (2019) Patterns in outpatient benzodiazepine prescribing in the united States. JAMA Netw Open. https:\/\/doi.org\/10.1001\/jamanetworkopen.2018.7399","journal-title":"JAMA Netw Open"},{"key":"3992_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13034-024-00757-5","author":"K Kurvits","year":"2024","unstructured":"Kurvits K, Toompere K, Jaanson P, Uusk\u00fcla A (2024) The COVID-19 pandemic and the use of benzodiazepines and benzodiazepine-related drugs in estonia: an interrupted time-series analysis. Child Adolesc Psychiatry Ment Health. https:\/\/doi.org\/10.1186\/s13034-024-00757-5","journal-title":"Child Adolesc Psychiatry Ment Health"},{"key":"3992_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.13811","author":"M H\u00f8jlund","year":"2023","unstructured":"H\u00f8jlund M et al (2023) Use of benzodiazepines and benzodiazepine-related drugs in the Nordic countries between 2000 and 2020. Basic Clin Pharmacol Toxicol. https:\/\/doi.org\/10.1111\/bcpt.13811","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"3992_CR32","doi-asserted-by":"publisher","DOI":"10.1370\/afm.1319","author":"JM Hoebert","year":"2012","unstructured":"Hoebert JM, Souverein PC, Mantel-Teeuwisse AK, Leufkens HGM, van Dijk L (2012) Reimbursement restriction and moderate decrease in benzodiazepine use in general practice. Ann Fam Med. https:\/\/doi.org\/10.1370\/afm.1319","journal-title":"Ann Fam Med"},{"key":"3992_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-029148","author":"LJ Stoker","year":"2019","unstructured":"Stoker LJ, Heerdink ER, Janssen R, Egberts TCG (2019) Effect of reimbursement restriction policy on the use of benzodiazepines in the netherlands: an interrupted time series analysis. BMJ Open. https:\/\/doi.org\/10.1136\/bmjopen-2019-029148","journal-title":"BMJ Open"},{"key":"3992_CR34","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14753","author":"M Istvan","year":"2021","unstructured":"Istvan M et al (2021) Change in the regulatory framework for zolpidem: what is the impact on the landscape of the prescription of sedative medications? The French national ZORRO study. Br J Clin Pharmacol. https:\/\/doi.org\/10.1111\/bcp.14753","journal-title":"Br J Clin Pharmacol"},{"key":"3992_CR35","unstructured":"Styraite G, Buka AA, Sarskute A, Vecmuktans D, Peceliuniene J (2020) Depression management in primary care in Lithuania and Latvia. 22:17\u201323"},{"key":"3992_CR36","doi-asserted-by":"publisher","DOI":"10.17605\/OSF.IO\/FJT8K","author":"T Lasys","year":"2025","unstructured":"Lasys T, Essink SCM et al (2025) Project repository - Impact of policy measures targeting benzodiazepines and Benzodiazepine-related drugs in lithuania: interrupted time series analysis. OSF. https:\/\/doi.org\/10.17605\/OSF.IO\/FJT8K","journal-title":"OSF"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03992-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-025-03992-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03992-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T09:54:33Z","timestamp":1773309273000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-025-03992-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["3992"],"URL":"https:\/\/doi.org\/10.1007\/s00228-025-03992-7","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"assertion":[{"value":"22 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"68"}}